ArticleBMC cancer2025
Cyclic cytokines mediated the effect of immune cells on meningioma: a two-step, mediation mendelian randomization study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningioma is a common central nervous system tumor that poses serious health hazards and increases with age. However, the role of immune cells in meningioma remains incompletely understood.
methodsData from genome-wide association studies on meningioma, cyclic cytokines, and immune cells were comprehensively analyzed. We conducted a two-step, two-sample mendelian randomization study to investigate the causal relationship between immune cell characteristics and meningioma. Furthermore, we examined the mediation effect of cyclic cytokines in connecting the association of immune cells with the risk of meningioma.
resultsEighteen immune phenotypes showed significant correlations with meningioma risk. Notably, Naive CD4-CD8- T cell %T Cell (OR: 1.380, 95% CI: 1.013-1.880, P = 0.041) and FSC-A on Myeloid Dendritic Cell (OR: 1.177, 95% CI: 1.045-1.325, P = 0.007) were implicated in promoting meningioma via MMP-1. The mediation effects of MMP-1 in these two immune cells were 0.023 and 0.015, with corresponding proportions of 7.110% and 8.981% in the mediation effect ratio.
conclusionOur study elucidated the causal relationship between immune cell phenotypes and meningioma, pinpointing the potential role of MMP-1. These findings provide clues for potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.